观察性药物流行病学研究的P值相关问题探讨

doi:10.19803/j.1672-8629.2022.01.05

中国药物警戒 ›› 2022, Vol. 19 ›› Issue (1): 23-26.
DOI: 10.19803/j.1672-8629.2022.01.05

• 真实世界数据支持药械监测与评价(一）专栏 • 上一篇下一篇

观察性药物流行病学研究的P值相关问题探讨

黎国威¹, 李立康¹, 刘颖欣¹, 王若婷¹, 吴大嵘^2,△

¹广东省第二人民医院,广东广州 510317;
²广东省中医院,广东省中医药科学院,广州中医药大学第二附属医院,广东广州 510120

收稿日期:2021-09-30 出版日期:2022-01-15 发布日期:2022-01-20
作者简介:黎国威,男,教授,临床流行病学、心脑血管研究。^△为并列第一作者。
基金资助:
国家重点研发计划（2019YFC1709800、2019YFC 1709802）

Common problems related to P-value in observational pharmacoepidemiological studies

LI Guowei¹, LI Likang¹, LIU Yingxin¹, WANG Ruoting¹, WU Darong^2,△

¹Guangdong Second Provincial General Hospital, Guangzhou Guangdong 510317, China;
²Guangdong Provincial Hospital of Chinese Medicine, Guangdong Provincial Academy of Chinese Medical Sciences, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou Guangdong 510120, China

Received:2021-09-30 Online:2022-01-15 Published:2022-01-20

摘要/Abstract

摘要： 目的探索观察性药物流行病学研究中P值相关的常见问题。方法通过文献研究结合专家经验等途径进行叙述性综述。结果在观察性药物流行病学研究中,P值的常见问题包括容易被错误解读与被人为操纵、基于P值是否小于0.05进行一刀切来判断结论是否具有统计学意义等,这些常见问题极容易损害药物流行病学研究结论的可重复性与真实有效性。结论药物流行病学研究容易出现P值的相关问题。通过综合提高对P值等基本概念的教育水平等多渠道,规范科学研究和临床实践,结合多方的联动努力,才能减缓当前P值不当使用的窘况,提高观察性药物流行病学研究结论的真实有效性与可重复性。

关键词: 药物流行病学, P值, 统计学, 观察性研究

Abstract: Objective To explore the common problems related to P-value in observational pharmacoe-pidemiological studies. Methods A combination of literature research and expert opinions was used for this review. Results The common problems related to P-value in observational pharmacoepidemiological studies included myths, misuse, manipulation and dichotomization of P-value. These problems could compromise the validity and reproducibility of findings and conclusions in pharmacoepidemiological studies. Conclusion Problems related to P-value often occur in observational pharmacoepidemiological studies. An integrated approach that involves advancing researchers' understanding of P-value, enhancing the quality and integrity of research and clinical practices, and ensuring proper use of P-value in the research community will help minimize the misuse of P-value in pharmacoepidemiological studies.

Key words: pharmacoepidemiology, P-value, statistical, observational study

中图分类号:

R994.11

黎国威, 李立康, 刘颖欣, 王若婷, 吴大嵘. 观察性药物流行病学研究的P值相关问题探讨[J]. 中国药物警戒, 2022, 19(1): 23-26.

LI Guowei, LI Likang, LIU Yingxin, WANG Ruoting, WU Darong. Common problems related to P-value in observational pharmacoepidemiological studies[J]. Chinese Journal of Pharmacovigilance, 2022, 19(1): 23-26.

参考文献

[1] FISHER RA.Statistical tests[J]. Nature, 1935, 136(3438): 474.
[2] BÉGAUD B. Dictionnary of pharmacoepidemiology[M]. Chichester, UK: John Wiley & Sons Ltd, 2000.
[3] GRIMES DA, SCHULZ KF.Bias and causal associations in observational research[J]. Lancet (London, England), 2002, 359(9302): 248-252.
[4] MA H, LI X, SUN D, et al.Association of habitual glucosamine use with risk of cardiovascular disease: prospective study in UK Biobank[J]. BMJ, 2019, 365: l1628.
[5] WASSERSTEIN RL, LAZAR NA.The ASA statement on p-values: context, process, and purpose[J]. The American Statistician, 2016, 70(2): 129-133.
[6] ALTMAN DG, BLAND JM.Statistics notes: Absence of evidence is not evidence of absence[J]. BMJ, 1995, 311(7003): 485.
[7] SIMMONS JPNL, SIMONSOHN U.False-positive psychology: undisclosed flexibility in data collection and analysis allows presenting anything as significant[J]. Psychological Science, 2011, 22(11): 1359-1366.
[8] MOTULSKY HJ.Common misconceptions about data analysis and statistics[J]. The Journal of Pharmacology and Experimental Therapeutics, 2014, 351(1): 200-205.
[9] LI G, KAMEL M, JIN Y, et al.Exploring the characteristics, global distribution and reasons for retraction of published articles involving human research participants: a literature survey[J]. Journal of Multidisciplinary Healthcare, 2018, 11: 39-47.
[10] CHAN AW.Bias, spin, and misreporting: time for full access to trial protocols and results[J]. PLoS Medicine, 2008, 5(11): e230.
[11] BOUTRON I, DUTTON S, RAVAUD P, et al.Reporting and interpretation of randomized controlled trials with statistically nonsignificant results for primary outcomes[J]. JAMA, 2010, 303(20): 2058-2064.
[12] WAKEFIELD AJ, MURCH SH, ANTHONY A,et al.Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children[J]. Lancet (London, England), 1998, 351(9103): 637-641.
[13] The Editors of The Lancet. Retracted-ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children[J]. Lancet (London, England), 2010, 375(9713): 445.
[14] LI G, WALTER S, THABANE L.Shifting the focus away from binary thinking of statistical significance and towards education for key stakeholders: revisiting the debate on whether it's time to de-emphasize or get rid of statistical significance[J]. J Clin Epidemiol, 2021, 137: 104-112.
[15] HURLBERT SH, LEVINE RA, UTTS J.Coup de grâce for a tough old bull:“Statistically significant”expires[J]. The American Statistician, 2019, 73(sup1): 352-357.
[16] WASSERSTEIN RL, SCHIRM AL, LAZAR NA.Moving to a world beyond“P< 0.05”[J]. The American Statistician, 2019, 73(sup1): 1-19.
[17] AMRHEIN V, GREENLAND S, MCSHANE B.Scientists rise up against statistical significance[J]. Nature, 2019, 567(7748): 305-307.
[18] BENJAMIN DJ, BERGER JO, JOHANNESSON M, et al.Redefine statistical significance[J]. Nature Human Behaviour, 2018, 2(1): 6-10.
[19] VAN CALSTER B, STEYERBERG EW, COLLINS GS, et al.Consequences of relying on statistical significance: some illustra-tions[J]. European Journal of Clinical Investigation, 2018, 48(5): e12912.
[20] STEYERBERG EW, VAN CALSTER B.Redefining significance and reproducibility for medical research: a plea for higher P-value thresholds for diagnostic and prognostic models[J]. European Journal of Clinical Investigation, 2020, 50(5): e13229.
[21] IOANNIDIS JP.Retiring statistical significance would give bias a free pass[J]. Nature, 2019, 567(7749): 461-462.
[22] FRICKER JR RD, BURKE K, HAN X, et al.Assessing the statistical analyses used in basic and applied social psychology after their P-value ban[J]. The American Statistician, 2019, 73(sup1): 374-384.

观察性药物流行病学研究的P值相关问题探讨

Common problems related to P-value in observational pharmacoepidemiological studies

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 8

编辑推荐

Metrics

[1]	耿颖, 刘毅, 王雪蕾, 谭德讲, 朱容蝶, 郭贤辉, 陈华, 郑丽娥. 近红外光谱法和统计学过程控制方法对亚叶酸钙药品对照品水分进行质量控制的研究[J]. 中国药物警戒, 2023, 20(11): 1221-1227.
[2]	王丽, 王晓墨, 杨晨露. 基于医疗大数据开展药品上市后监测与评价研究的偏倚及其控制[J]. 中国药物警戒, 2022, 19(3): 239-243.
[3]	李新旭, 唐智敏, 周军, 谭明敏, 卢明亮, 王景朝, 王骏. 对药物研发与技术审评沟通交流中常见统计学专业问题的探讨[J]. 中国药物警戒, 2022, 19(2): 169-175.
[4]	胡方圆, 叶小飞, 许金芳, 郭晓晶, 贺佳. 使用常规收集的卫生数据开展药物流行病学研究报告规范（RECORD-PE）及解读[J]. 中国药物警戒, 2019, 16(3): 144-148.
[5]	韩贺东,郭威,叶小飞,许金芳,郭晓晶,朱田田,史文涛,王蒙,侯永芳,贺佳. 目标最大似然估计在药品安全性主动监测中的应用[J]. 中国药物警戒, 2017, 14(6): 341-345.
[6]	吴斌,吴建茹,钟翎,林宇,张业象. 广东省四地市医疗机构参麦注射液不合理用药情况分析[J]. 中国药物警戒, 2016, 13(4): 236-239.
[7]	朱田田, 叶小飞, 郭晓晶, 张天一, 汪晶, 史文涛, 贺佳. 基于电子医疗数据库的药物流行病学安全性研究的特点及要求[J]. 中国药物警戒, 2014, 11(7): 413-315.
[8]	王大猷. 药品不良反应监测的定义和范畴研究[J]. 中国药物警戒, 2014, 11(12): 732-738.